Informations générales (source: ClinicalTrials.gov)
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
Interventional
Phase 2
Bristol-Myers Squibb (Voir sur ClinicalTrials)
août 2019
août 2029
20 novembre 2024
Main Objective of this study is to examine long-term safety of nivolumab monotherapy
including combinations and other cancer therapies in various tumor types.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Christos CHOUAID | 06/05/2024 13:54:03 | Contacter | ||
| CLCC INSTITUT GUSTAVE ROUSSY | Caroline ROBERT | 29/05/2024 15:58:06 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Europeen Georges Pompidou | Stephane Oudard, Site 0167 | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| APHM - Hopital de la Timone - 13385 - Marseille - France | Caroline Gaudy, Site 0125 | Contact (sur clinicalTrials) | |||
| Centre Georges-Francois Leclerc - 21079 - Dijon Cedex - France | Coureche Kaderbhai, Site 0109 | Contact (sur clinicalTrials) | |||
| Centre Hospitalier Lyon Sud - 69495 - Pierre-Benite Cedex - France | Stephane Dalle, Site 0084 | Contact (sur clinicalTrials) | |||
| Centre Hospitalier Universitaire de Bordeaux Hospital Saint Andre - 33075 - Bordeaux - Gironde - France | Caroline Dutriaux, Site 0006 | Contact (sur clinicalTrials) | |||
| Centre Jean Perrin - 63011 - Clermont-Ferrand - France | Hakim Mahammedi, Site 0345 | Contact (sur clinicalTrials) | |||
| CHU Dijon - 21000 - Dijon Cedex - France | Sophie Dalac, Site 0074 | Contact (sur clinicalTrials) | |||
| CHU Grenobles Alpes - 38700 - La Tronche - France | Julie Charles, Site 0010 | Contact (sur clinicalTrials) | |||
| Hopital Musse - 83 056 - Toulon - France | Clarisse Audigier-Valette, Site 0156 | Contact (sur clinicalTrials) | |||
| Hospital Saint-Louis - 75010 - Paris - France | Celeste Lebbe, Site 0028 | Contact (sur clinicalTrials) | |||
| Local Institution - 0029 - 94800 - Villejuif - France | Site 0029 | Contact (sur clinicalTrials) | |||
| Local Institution - 0153 - 13915 - Marseille Cedex 20 - France | Site 0153 | Contact (sur clinicalTrials) | |||
| Local Institution - 0182 - 34090 - Montpellier - France | Site 0182 | Contact (sur clinicalTrials) | |||
| Local Institution - 0300 - 44093 - Nantes - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 0301 - 75018 - Paris - France | Site 0301 | Contact (sur clinicalTrials) | |||
| Local Institution - 0341 - 44093 - Nantes - France | Site 0341 | Contact (sur clinicalTrials) | |||
| Local Institution - 0362 - 54500 - Vandoeuvre-Les-Nancy - Meurthe-Et-Moselle - France | Site 0362 | Contact (sur clinicalTrials) | |||
| Local Institution - 31059 - Toulouse Cedex - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 34295 - Montpellier - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 35033 - Rennes - France | Contact (sur clinicalTrials) | ||||
| Pole Biologie Pathologie Genetique - CHU de Lille - 59037 - Lille Cedex - France | Laurent Mortier, Site 0011 | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Signed Written Informed Consent.
- Eligible to receive continued study treatment per the Parent Study, including
treatment beyond progression per investigator assessment in the Parent Study.
- On treatment hold in the Parent Study following long-lasting response or are
eligible for treatment rechallenge as defined in the Parent Study.
- WOCBP and male participants who are sexually active must agree to follow
instructions for method(s) of contraception as described below and included in the
ICF.
- Signed Written Informed Consent.
- Eligible to receive continued study treatment per the Parent Study, including
treatment beyond progression per investigator assessment in the Parent Study.
- On treatment hold in the Parent Study following long-lasting response or are
eligible for treatment rechallenge as defined in the Parent Study.
- WOCBP and male participants who are sexually active must agree to follow
instructions for method(s) of contraception as described below and included in the
ICF.
- Participant is not eligible for study treatment per the Parent Study eligibility
criteria.
- Participants not receiving clinical benefit as assessed by the Investigator.
- Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness
which, in the opinion of the Investigator, indicates that participation in the study
is not in the best interest of the participant.
- Other protocol-defined Inclusion/Exclusion Criteria apply